allergy patient News
-
Allovate Therapeutics Provides Free Allerdent To Physicians
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of ...
-
Intrommune Therapeutics Launches #PeanutAllergyStrong
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the launch of its #PeanutAllergyStrong patient engagement campaign. “Supporting peanut allergy patients and their loved ones has always been the central mission at ...
-
Neurent Medical`s RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan
Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues LONDON, Nov. 13, 2018 /CNW/ -- Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises Neurent Medical with the 2018 European New Product Innovation Award for developing a ...
-
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose ...
-
Common invasive weed brings hay-fever allergies to Europe
A surprising number of people in Europe are suffering from allergies caused by the common ragweed, Ambrosia artemisiifolia, according to a recent study. The researchers recommend a co-ordinated European monitoring programme to track the spread of this invasive alien plant. The common ragweed is a native plant of North America, where it is a leading cause of hay-fever type allergies. Symptoms ...
-
Research at our core
Rejoint has teamed up with the Fraunhofer Project Centre at the University of Twente in Netherlands, and the Fruanhofer Institute for Production Technology (IPT) in Aachen, Germany, in order to develop and validate a titanium tibial tray with an embedded lattice structure for accelerating the osseointegrative process of YourKnee, Rejoint's 3D printed patient-specific implant for TKR. It will ...
By Rejoint SRL
-
GI Innovation sings MoU for a new biopharmaceutical development with Merck
-Accelerating for development of high expression cell line through combination of GI-SMARTTM platform technology of GI Innovation and CHOZN® Platform of Merck -Expecting synergy of both companies for biopharmaceutical development using CHOZN® Platform, supplying subsidiary materials, education consulting, and etc.,. GI Innovation Co., Ltd. announced that it signed MoU for a ...
-
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. “Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant ...
-
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...
-
How to adjust the spray bottle into a mist
Press the gas first, maybe the air pressure is not enough. If the air pressure is sufficient, adjust the plastic screw at the front end of the nozzle. In the spray can, the liquid and a gas which can be ejected by the fine particles are stored under a pressurized state. In the past, a gas called a chlorofluorocarbon was placed in a spray can, which was harmful to the environment. Many spray ...
-
Allovate Therapeutics Appoints Bob Pomrenke as CEO
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
-
Allovate and Restore Health Sign Exclusive Agreement to Bring Allerdent, the First Anti-Allergy Toothpaste System, to Allergy Sufferers
Allovate, LLC, a specialty biopharmaceutical company, today announced that the company has signed an exclusive provider agreement with Restore Health to bring the new Allerdent OMIT System™, a personalized toothpaste system for the delivery of allergy immunotherapy, to patients nationwide. Allerdent™ is the first oral mucosal immunotherapy (OMIT) toothpaste system designed to help ...
-
HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene-Verordnung (TAV). The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing ...
-
Allovate Therapeutics Announces Issuance of U.S. Patent Covering Novel Oral Mucosal Immunotherapy Platform
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with ...
-
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 ...
-
New Blood Tests Help Assess Asthma Risk and Decide Pet Selection
AACC 2019 – New blood tests may help healthcare providers identify if patients are sensitized to up to 11 different molecular allergen component proteins found in dogs, cats, or horses. The assays analyze sensitivity to specific proteins found in the skin, fur and saliva of these animals. ImmunoCAP Allergen Components test for Furry Animal have been cleared by the U.S. Food & Drug ...
-
Neurent raises €9.3m to put paid to chronic runny noses
An Irish company developing a breakthrough therapy for a common nasal condition has raised €9.3 million. Neurent Medical, based in Oranmore, Co Galway, is developing a medical device that would allow doctors treat patients with rhinitis in their offices, rather than in a surgical setting. The funding round was led by Fountain Healthcare Partners, the Irish life sciences fund. Others ...
-
Intrommune Therapeutics to Present at BIO Digital 2021
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. The event will be live June 10-11 & 14-18, 2021. Michael Nelson, JD, Co-Founder and CEO will provide an overview of ...
-
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. INT301 is a novel peanut desensitization immunotherapy formulated as ...
-
TargetSolutions’ EMS Continuing Education Course Examines Emergency Care for Allergies and Anaphylaxis
TargetSolutions’ EMS Allergies and Anaphylaxis Basic training course covers the topics of allergy-related incidents and the appropriate care needed in such situations. Allergic reactions can develop as simple irritations, but quickly mobilize into life-threatening emergencies. EMS responders are tasked with determining the severity of the condition as emergency medical care and rapid ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you